Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Promotion of Fas-mediated apoptosis in Type II cells by high doses of hepatocyte growth factor bypasses the mitochondrial requirement.

Journal of cellular physiology | 2007

The death receptor pathway is coupled to the mitochondria apoptosis pathway. However, mitochondrial participation, which is stimulated by Bid but suppressed by Bcl-2/Bcl-x(L), is required in certain cells (Type II), but not in others (Type I). While these differences were originally characterized in the lymphoid cell lines, the typical Type II cells are represented by hepatocytes in vivo. The molecular mechanisms that distinguish Type II from Type I cells and the regulation are not fully understood. Fas can be sequestered by the HGF receptor c-Met and high doses of HGF can promote cell death by freeing Fas from c-Met complex. We thus reasoned that treatment of the Type II cells with high doses of HGF could enhance Fas-mediated apoptosis and spare the mitochondria amplification. Indeed, such treatment led to increased apoptosis in Type II lymphoid cells, which could not be blocked by Bcl-x(L). Moreover, significant hepatocyte apoptosis was induced by this scheme in the absence of Bid with increased dissociation of Fas from c-Met. These findings indicate that high doses of HGF could be used to promote apoptosis in Type II cells bypassing the requirement for mitochondria activation.

Pubmed ID: 17620325 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R56 CA095782
  • Agency: NCATS NIH HHS, United States
    Id: UL1 TR000005
  • Agency: NCI NIH HHS, United States
    Id: CA35373
  • Agency: NCI NIH HHS, United States
    Id: R01 CA095782
  • Agency: NIEHS NIH HHS, United States
    Id: ES006109
  • Agency: NCI NIH HHS, United States
    Id: R01 CA103958-05
  • Agency: NCI NIH HHS, United States
    Id: R01 CA103958
  • Agency: NCI NIH HHS, United States
    Id: CA111456
  • Agency: NCI NIH HHS, United States
    Id: R01 CA111456-03
  • Agency: NCI NIH HHS, United States
    Id: R01 CA035373
  • Agency: NCI NIH HHS, United States
    Id: R01 CA035373-26
  • Agency: NIEHS NIH HHS, United States
    Id: R01 ES006109
  • Agency: NCI NIH HHS, United States
    Id: R01 CA083817-07
  • Agency: NCI NIH HHS, United States
    Id: CA95782
  • Agency: NCI NIH HHS, United States
    Id: CA84817
  • Agency: NCI NIH HHS, United States
    Id: R01 CA111456
  • Agency: NCI NIH HHS, United States
    Id: R01 CA083817

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


BIOMOL (tool)

RRID:SCR_013545

An Antibody supplier

View all literature mentions